The reduction in DNase I activity observed in RA patients results from a complex interplay of factors including molecular inhibitors (G-actin, autoantibodies), an adverse synovial environment (altered ionic composition, increased ROS, low pH, proteases), and potentially genetic regulation (hypermethylation of DNASE1 promoter region). This evidence concerns the gene DNASE1 and rheumatoid arthritis.